Intercept Pharmaceuticals, Inc. may struggle to preserve the future of its primary biliary cholangitis drug Ocaliva (obeticholic acid) following the US Food and Drug Administration’s negative review of a confirmatory trial and real-world evidence study.
Intercept Pharmaceuticals, Inc., a wholly owned subsidiary of Alfasigma S.p.A
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?